Loading stock data…
Hims & Hers Health (HIMS)
$28.09-4.65 (-14.20%)
Market ClosedLast close Jul 24
Hims & Hers Health, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Hims & Hers Health, Inc. in the Healthcare sector is trading at $28.09 with a market capitalization of $7.2B. Wall Street consensus targets $29.77 (13 analysts), implying a +6.0% move over the next 12 months. The stock is currently 60% below its 52-week high of $70.43, remaining 9.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 22) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $608.10M↓ | $617.82M↑ | $598.98M↑ | $544.83M↓ | $586.01M |
| Gross Profit | $396.79M↓ | $444.44M↑ | $442.06M↑ | $416.20M↓ | $430.69M |
| Operating Income | -$78.32M↓ | $9.19M↓ | $11.81M↓ | $26.72M↓ | $57.90M |
| Net Income | -$92.11M↓ | $20.60M↑ | $15.77M↓ | $42.51M↓ | $49.48M |
Peer Comparison
JNJUNHPFE
Fundamentals
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and int...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.97%
Volume
Today's trading volume
28.33M
Recent News
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month
Joe Spector helped build a multibillion-dollar telehealth company. Now he’s on to own remote vet services.
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
Hims & Hers Health Inc. is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to legally produce them. FDA Panel Splits,...
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder
Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the news means for HIMS stock.
Hims & Hers (HIMS) Stock Looks Cheap On Cash Flow But Pricey After A 313% Run
Hims & Hers Health stock has delivered a very large 5 year gain, yet the latest valuation work suggests the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and supporting market multiples. Over 5 years, Hims & Hers Health has returned 312.9%, which puts the current debate squarely on whether earlier investors have already captured most of the value or if the rerating still has room to run. The outcome of the recent FDA peptide...